MARKET

JSPRW

JSPRW

Jasper Therapeutics Inc
NASDAQ
0.0130
0.00
0.00%
Opening 09:30 05/29 EDT
OPEN
--
PREV CLOSE
0.0130
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.1475
52 WEEK LOW
0.0101
MARKET CAP
--
P/E (TTM)
-0.0040
1D
5D
1M
3M
1Y
5Y
1D
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
NASDAQ · 4d ago
Weekly Report: what happened at JSPR last week (0518-0522)?
Weekly Report · 4d ago
Jasper Therapeutics Announces Board Resignation and Committee Change
TipRanks · 05/21 21:40
Jasper Therapeutics director Christian Nolet resigns from board
PUBT · 05/21 20:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/19 12:05
Weekly Report: what happened at JSPR last week (0511-0515)?
Weekly Report · 05/18 09:49
Cisco, Arista, Jasper, StoneCo, Lisata Trending With Analysts
TipRanks · 05/16 09:01
Jasper Therapeutics Cut to Hold From Buy by TD Cowen
Dow Jones · 05/15 16:55
More
About JSPRW
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPRW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPRW stock methods without spending real money on the virtual paper trading platform.